BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26021203)

  • 1. Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility?
    Gerson LB
    Gastroenterol Clin North Am; 2015 Jun; 44(2):425-38. PubMed ID: 26021203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
    Barbiere JM; Lyratzopoulos G
    Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
    Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
    Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
    Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
    Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
    Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations.
    Hirst NG; Gordon LG; Whiteman DC; Watson DI; Barendregt JJ
    J Gastroenterol Hepatol; 2011 Feb; 26(2):247-54. PubMed ID: 21261712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
    Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
    Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic interventions in Barrett's esophagus: Do the dollars make sense?
    Chennat J; Ferguson MK
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):145-53. PubMed ID: 21112504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and surveillance of Barrett's esophagus.
    Regula J
    Dig Dis; 2009; 27(1):54-7. PubMed ID: 19439961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The wizards of odds: cost-effectiveness, Barrett's screening, and surveillance guidelines.
    Perdue DG; Murray J; Wang KK
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):865-7. PubMed ID: 15476149
    [No Abstract]   [Full Text] [Related]  

  • 16. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
    Gerson L; Lin OS
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rationale for screening and surveillance of Barrett's metaplasia.
    Wani S; Sharma P
    Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.